Appetite (Eating) Disorders - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 42 pages report, published by Global Markets Direct

Keywords : Appetite (Eating) Disorders Therapeutic Products under Development, Key Players in Appetite (Eating) Disorders Therapeutics, Appetite (Eating) Disorders Pipeline Overview, Appetite (Eating) Disorders Pipeline, Appetite (Eating) Disorders Pipeline Assessment

Report ThumbnailSeptember-2013
Appetite (Eating) Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Appetite (Eating) Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Appetite (Eating) Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Appetite (Eating) Disorders. Appetite (Eating) Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Appetite (Eating) Disorders.
- A review of the Appetite (Eating) Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Appetite (Eating) Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Appetite (Eating) Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Appetite (Eating) Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Appetite (Eating) Disorders, H2 2013 7
  • Products under Development for Appetite (Eating) Disorders - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Mid Clinical Stage Products, H2 2013 10
  • Discovery and Pre-Clinical Stage Products, H2 2013 11
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Appetite (Eating) Disorders, H2 2013 7
  • Products under Development for Appetite (Eating) Disorders - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 11
  • Products under Development by Companies, H2 2013 12
  • GlaxoSmithKline plc, H2 2013 13
  • INSYS Therapeutics, Inc., H2 2013 14
  • Global Health Ventures Inc., H2 2013 15
  • Omeros Corporation, H2 2013 16
  • Medisyn Technologies, Inc., H2 2013 17
  • Kuhnil Pharmaceutical Co., Ltd., H2 2013 18
  • MAKScientific, LLC, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Appetite (Eating) Disorders Therapeutics - Drug Profile Updates 34
  • Appetite (Eating) Disorders Therapeutics - Dormant Products 35
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Appetite (Eating) Disorders Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Appetite (Eating) Disorders 7
  • Appetite (Eating) Disorders Therapeutics under Development by Companies 9
  • Mid Clinical Stage Products 10
  • Comparative Analysis 10
  • Discovery and Pre-Clinical Stage Products 11
  • Comparative Analysis 11
  • Appetite (Eating) Disorders Therapeutics - Products under Development by Companies 12
  • Companies Involved in Appetite (Eating) Disorders Therapeutics Development 13
  • GlaxoSmithKline plc 13
  • INSYS Therapeutics, Inc. 14
  • Global Health Ventures Inc. 15
  • Omeros Corporation 16
  • Medisyn Technologies, Inc. 17
  • Kuhnil Pharmaceutical Co., Ltd. 18
  • MAKScientific, LLC 19
  • Appetite (Eating) Disorders - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • GSK-1521498 - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • GPR101 Antagonist - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • dronabinol - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • cianidanol - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • KI-1003 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Dopamine Inhibitor - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Drug Targeting GPR82 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • AM-6527 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Appetite (Eating) Disorders Therapeutics - Drug Profile Updates 34
  • Appetite (Eating) Disorders Therapeutics - Dormant Products 35
  • Appetite (Eating) Disorders - Product Development Milestones 36
  • Featured News & Press Releases 36
  • Aug 08, 2012: Lightlake Therapeutics Announces Positive Preliminary Phase II Clinical Trial Results Of Binge Eating Disorder Treatment 36
  • May 03, 2012: Lightlake Announces Positive Preliminary Phase II Trial Results Of Binge Eating Disorder Treatment Using Naloxone 37
  • Apr 26, 2012: Shire Reports Positive Top-Line Results From Phase II Study Of Vyvanse In Adults With Binge Eating Disorder 38
  • Mar 02, 2011: Omeros Unlocks Orphan GPCRs Linked To Pancreatic Cancer And Cognitive Disorders 40
  • Appendix 41
  • Methodology 41
  • Coverage 41
  • Secondary Research 41
  • Primary Research 41
  • Expert Panel Validation 41
  • Contact Us 42
  • Disclaimer 42

Please select a license type

Share

Related Products

Global Markets DirectAppetite (Eating) Disorders - Pipeline Review, H2 2013Product ThumbnailAppetite (Eating) Disorders - Pipeline Review, H2 2013, Industry ReportProduct #: 113338
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved